Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 2 institutions in 1 country.
Viviana De LucaDepartment of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, 80131 Naples, Italy.
Andrea AngeliNeurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0002-1470-7192
Alessio NocentiniNeurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0003-3342-702X
Paola GratteriNeurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0002-9137-2509
Silvia PratesiDepartment of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.
Damiano TaniniDepartment of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0001-8930-3566
Vincenzo CarginaleDepartment of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, 80131 Naples, Italy.ORCID 0000-0002-1842-494X
Antonella CapperucciDepartment of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.
Claudiu T SupuranNeurofarba Department, Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0003-4262-0323
Clemente CapassoDepartment of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, 80131 Naples, Italy.ORCID 0000-0003-3314-2411
University of Florence · ITInstitute of Biosciences and Bioresources · IT
Funding
Italian National Research Council (CNR) Grant COVPI- Tackling coronaviruses-related diseases by developing viral Protease Inhibitors
6 · The paper itself
Abstract
The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate the impact of COVID-19 pandemic. The present study examines the strategic application of the SARS-CoV-2 Main Protease (M
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Leveraging SARS-CoV-2 Main Protease (M · full record | OpenQuestion